The Top 5 Biosimilars Articles for the Week of February 10

The Center for Biosimilars® recaps the top stories for the week of February 10, 2020.
February 14, 2020


Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of February 10, 2020.

Number 5: The European League Against Rheumatism (EULAR) updates guidelines to address recommendations on the use of disease-modifying antirheumatic drugs and glucocorticoids to treat patients with rheumatoid arthritis.

Number 4: Patents on nearly 20 oncology biologics will expire by 2023, which could lead to more biosimilars in cancer care and lower costs, a review article says.

Number 3: At the Specialty Therapies and Biosimilars Congress, a review of the orphan drug market predicts hefty biosimilar competition, although patent struggles need resolution, according to one speaker.

Number 2: Also at the Congress, the director of pharmacy for Emory Healthcare discusses how they developed a strong in-house specialty pharmacy and cut dependence on outside for-profit specialty pharmacies and managed to strengthen adherence and improve patient outcomes.

Number 1: A review of the 2020 pipeline shows oncology biosimilars are starting to gain some traction in the marketplace.

To read all of these articles and more, visit centerforbiosimilars.com.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.